Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9Hyperandrogenism 4Neoplasms 3Skin Diseases 1Sarcoma 1Rare Diseases 1Obesity 1Metabolic Syndrome 1Lymphoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hematologic Neoplasms 1Heart Failure 1Glioblastoma 1Endocrine System Diseases 1Critical Illness 1Cardiovascular Diseases 1Cardiotoxicity 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acute Kidney Injury 1Acanthosis Nigricans 1

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3selpercatinib 2parathyroid hormone-related peptide (1-36) 2niraparib 2Ocoxin 2Musculoskeletal Manipulations 2Metformin 2Clomiphene 2Cisplatin 2repotrectinib 1relacorilant 1pralsetinib 1pembrolizumab 1napabucasin 1fluorodopa F 18 1anlotinib 1adrenosterone 1Thalidomide 1Sunitinib 1Spironolactone 1Parathyroid Hormone-Related Protein 1Parathyroid Hormone 1Paclitaxel 1Octreotide 1Melphalan 1Leuprolide 1Irinotecan 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endocrine System Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡